The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...
The UK-US deal does not resolve every challenge – no single agreement could. But it marks a meaningful step toward restoring ...
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Singaporean Health Sciences Authority (HSA) say the ...
RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series ...
Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer ...
Drug delivery is no longer just about convenience. It’s about enabling the therapies of the future to succeed where they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback